Refractory chronic myelogenous leukemia, BCR-ABL1 positive
Clinical trials for Refractory chronic myelogenous leukemia, BCR-ABL1 positive explained in plain language.
Never miss a new study
Get alerted when new Refractory chronic myelogenous leukemia, BCR-ABL1 positive trials appear
Sign up with your email to follow new studies for Refractory chronic myelogenous leukemia, BCR-ABL1 positive, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could detoxing metals boost chemo for leukemia?
Disease control Recruiting nowThis early-stage trial is testing whether two drugs that lower metal levels in the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. The study will enroll 58 adults and aims to find the safest dose and check f…
Matched conditions: REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a Tumor's own cells reveal the best drug for each child?
Disease control Recruiting nowThis trial explores whether testing a child's own tumor cells against a panel of approved drugs can help doctors choose a personalized treatment plan. It enrolls children and young adults up to age 21 with recurrent or refractory cancers, including leukemias, lymphomas, and solid…
Matched conditions: REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase 1 • Sponsor: Florida International University • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New chemo cocktail targets tough leukemias
Disease control Recruiting nowThis phase 2 trial is testing a combination of four chemotherapy drugs—cladribine, idarubicin, cytarabine, and venetoclax—in people with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blast-phase chronic myeloid leukemia. The goal is to see if this mix can kill ca…
Matched conditions: REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC